Trial Profile
Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Digoxin (Primary) ; Ivabradine (Primary)
- Indications Chronic heart failure; Left ventricular dysfunction
- Focus Therapeutic Use
- Acronyms DIVA-REF
- 03 Mar 2014 New trial record